 |
|
Plasma Tumor Necrosis Factor Levels in Patients With Presumed SepsisResults in Those Treated With Antilipid A Antibody vs Placebo
Mary Ann de Groote, MD;
Michael A. Martin, MD;
Peter Densen, MD;
Michael A. Pfaller, MD;
Richard P. Wenzel, MD, MSc
JAMA. 1989;262(2):249-251.
Abstract
| |
Using an enzyme-linked immunosorbent assay, we measured plasma levels of tumor necrosis factor (TNF) in 38 patients who were treated with either antilipid A antibody or a placebo for presumed gram-negative bacteremia. Sixteen of the 38 patients had positive blood cultures: 14 with gram-negative rods and 2 with Streptococcus pneumoniae. Initial serum samples for TNF determinations were obtained within 2 to 72 hours (mean, 18.8 hours) after the onset of clinical signs of sepsis. Six (16%) of 38 patients had detectable TNF levels: 4 of 14 with positive blood cultures for gram-negative rods but only 2 of 22 with negative blood cultures (odds ratio, 4; 95% confidence limits, 0.5 and 24.3). Of the 6 patients, 4 had received the placebo and 2 had received the antibody. Tumor necrosis factor levels did not predict adult respiratory distress syndrome, shock, disseminated intravascular coagulation, renal failure, or mortality. The highest TNF levels (500 and 250 pg/mL) were observed in 2 patients with Enterobacter cloacae bacteremia who had received the placebo and antilipid A antibody, respectively. The other 2 patients with bacteremia and detectable TNF levels had positive blood cultures for Haemophilus influenzae (50 pg/mL) and Bacteroides fragilis (120 pg/mL), respectively. Despite negative blood cultures, the remaining 2 patients repeatedly had detectable TNF levels and a clinical picture consistent with gram-negative sepsis.
(JAMA. 1989;262:249-251)
Author Affiliations
From the Divisions of Clinical Epidemiology (Drs de Groote, Martin, and Wenzel) and Infectious Diseases (Drs de Groote and Densen), Department of Internal Medicine, and Special Microbiology Laboratory, Department of Pathology (Dr Pfaller), University of Iowa College of Medicine, Iowa City; and the Department of Medicine, Veterans Administration Medical Center, Iowa City, Iowa (Drs de Groote and Densen). Dr de Groote is now with the Department of Medicine, University of Colorado School of Medicine, Denver. Dr Martin is now with the Department of Medicine, University of Maryland Medical School, Baltimore.
Footnotes
Reprint requests to Division of Clinical Epidemiology, Department of Internal Medicine, C-41 GH, University of Iowa, Iowa City, IA 52242 (Dr Wenzel).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Limulus Antilipopolysaccharide Factor-Derived Peptide Exhibits a New Immunological Activity with Potential Applicability in Infectious Diseases
Vallespi et al.
CVI 2000;7:669-675.
ABSTRACT
| FULL TEXT
Differential susceptibility of rhesus monkeys to high doses of endotoxin
Veloso et al.
Innate Immunity 1995;2:411-420.
ABSTRACT
Natural Cytokine Antagonists and Endogenous Antiendotoxin Core Antibodies in Sepsis Syndrome
Goldie et al.
JAMA 1995;274:172-177.
ABSTRACT
Normothermia Versus Hypothermia During Cardiopulmonary Bypass: A Randomized, Controlled Trial
Tonz et al.
Ann. Thorac. Surg. 1995;59:137-143.
ABSTRACT
| FULL TEXT
Delayed Tumor Necrosis Factor {alpha} Blockade Attenuates Pulmonary Dysfunction and Metabolic Acidosis Associated With Experimental Gram-negative Sepsis
Windsor et al.
Arch Surg 1994;129:80-89.
ABSTRACT
A Critical Evaluation of New Agents for the Treatment of Sepsis
Bone
JAMA 1991;266:1686-1691.
ABSTRACT
The Pathogenesis of Sepsis
Bone
ANN INTERN MED 1991;115:457-469.
ABSTRACT
Tumor Necrosis Factor in Sepsis
Leroux-Roels and Oftner
JAMA 1990;263:1494-1495.
ABSTRACT
Reporting of HIV Testing
Harkess and Istre
JAMA 1990;263:36-37.
ABSTRACT
|
